Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.814139
Title: Gut hormones and peptide therapeutics for diabetes
Author: Flatt, P. R.
Awarding Body: Ulster University
Current Institution: Ulster University
Date of Award: 2018
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Restricted access.
Access from Institution:
Abstract:
Research presented in this thesis has revealed exciting possibilities for exploiting normal physiological mechanisms triggered by incretin and other gut hormones for treatment of diabetes. A major theme has been the design of different families of enzyme resistant forms of GIP, GLP-1, CCK and oxyntomodulin by modification or substitution of amino acids at strategic sites. Further extension of bioactivity was achieved by acylation or mini- PEGylation. Stable forms of these peptides alone or in combination were shown to represent a novel and highly effective means of treating of obesity-diabetes. Such effects were mediated through a variety of mechanisms including stimulation of insulin secretion, promotion of beta cell function and, with exception of GIP agonists, inhibition of feeding and body weight loss. Remarkably, novel GIP receptor antagonists also ameliorated diabetes but by alleviation of insulin resistance and promotion of beta cell rest. These effects were secondary to inhibition of GIP-mediated lipogenesis and depletion of tissue triglycerides. Novel analogues of oxyntomodulin exhibited antidiabetic effects at both islet and extrapancreatic sites by dual agonism of GLP-1 and glucagon receptors. This discovery prompted work leading to development and characterisation of a series of unique unimolecular di- or tri-agonist peptides capable of activating receptors for GLP-1, glucagon and GIP. Such agents ameliorated diabetes, restored beta cell function and improved both lipid profile and body weight loss. Stable analogues also countered defects in cognition and bone quality revealing hitherto unappreciated actions of incretins. Alpha cell production of GLP-1 and GIP, driven by changes in relative expression of pro-convertases PC2 and PC1/3, were shown to be instrumental in the beta cell compensatory responses to pregnancy and metabolic stress. This research substantially advances knowledge on incretin and related gut hormones, revealing considerable potential of their stable peptide analogues and activation pathways for the effective treatment of diabetes in man.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.814139  DOI: Not available
Keywords: Incretin ; GLP-1 ; GIP ; PYY ; Oxyntomodulin ; Glucagon
Share: